Boehringer Ingelheim acquires Funxional products

German family-controlled drug major Boehringer Ingelheim has entered an agreement to acquire the global rights to privately-held UK company Funxional Therapeutics’ FX125L compound and somatotaxin program. Financial terms of the transaction were not revealed.

FX125L is a small molecule to treat a broad range of inflammatory diseases and was recently studied in a Phase II clinical trial in patients. Boehringer Ingelheim will be responsible for all further research, development and commercialization of FX125L.

"Boehringer Ingelheim is delighted to add another promising compound to its development pipeline of drugs for the treatment of respiratory disease, one of its most important therapeutic areas", said Klaus Dugi, corporate senior vice president medicine at the German fir, adding that, "by acquiring the Funxional Therapeutics program, we are looking forward to bringing a potential new therapy to patients, for instance those suffering from asthma and COPD."